Comparing the current results to its competitors, Neumora Therapeutics Inc reported Revenue decrease in the 2 quarter 2026 year on year by 0 %, despite the revenue increase by the most of its competitors of 32.73 %, recorded in the same quarter.
Neumora Therapeutics Inc , despite income growth by most of its competitors recorded a net loss, despite income increase by most of its competitors of 6978.2 %
Neumora Therapeutics Inc 's Comment on Competition and Industry Peers
The company operates in the biopharmaceutical and biotechnology sectors, focusing on therapeutics for neuropsychiatric disorders and neurodegenerative diseases. Its competitors include major biopharmaceutical and biotechnology companies, academic institutions, governmental agencies, consortiums, and both public and private research institutions, many of which have substantially greater resources. Specifically named competitors are Axsome Therapeutics, Denali Therapeutics, Neurocrine Biosciences, Prothena Corporation, and Xenon Pharmaceuticals.
May 14, 2024
Neumora Therapeutics, a renowned pharmaceutical company, has made significant strides towards developing innovative treatments for bipolar depression and schizophrenia. After a series of research success, the company recently announced the initiation of a Phase 2 trial for Navacaprant, an advanced therapeutic drug focused on treating bipolar depression, exhibiting potential to alleviate unmet needs associated with depressed mood and anhedonia.Navacaprant has already proven its ability to improve depressed mood and anhedonia symptoms during a prior Phase 2 study in major depressive disorder (MDD). Many experts now believe that this promising treatment could potentially revolutionize the management of bipolar ...
May 6, 2024
In an exciting development in the pharmaceutical sphere, Neumora Therapeutics, Inc. (Nasdaq: NMRA), a prominent clinical-stage biopharmaceuti...
November 27, 2023
Neumora Therapeutics Initiates Promising Clinical Study for Schizophrenia Treatment with Novel M4 Muscarinic Receptor Modulator Neumora Therapeutics, a renowned pharmaceutical company known for its innovative approaches in developing effective treatments for mental health disorders, has recently announced the initiation of a groundbreaking Phase 1 clinical study for NMRA-266. This new drug, a highly selective positive allosteric modulator of the M4 muscarinic receptor, holds great promise in addressing schizophrenia – a complex and debilitating psychiatric disorder. Schizophrenia affects millions of individuals worldwide, disrupting their thoughts, behavior, and emotions. It poses significant chall...
Amgen Inc.s business model focuses on leveraging advanced biotechnology to create therapeutic products for various diseases, particularly in the fields of oncology, inflammation, and cardiovascular health. The company invests heavily in research and development to drive innovation, while also utilizing strategic partnerships and acquisitions to enhance its product pipeline. Additionally, Amgen emphasizes a strong global commercial presence to maximize the accessibility and impact of its therapeutics in the healthcare market.
Coherus Biosciences Inc is a biopharmaceutical company focused on developing and commercializing high-quality biosimilar therapeutics. Their business model revolves around leveraging their expertise in cell culture, protein purification, formulation development, and analytical methods to manufacture and market biosimilar products. By providing cost-effective alternatives to expensive biologic drugs, Coherus Biosciences aims to make healthcare more accessible and affordable for patients.
Gilead Sciences Incs business model centers on researching, developing, and marketing innovative medicines, primarily targeting antiviral therapies. They focus on addressing unmet medical needs to enhance patient health globally.
Halozyme Therapeutics Inc is a biotechnology company that primarily focuses on developing and commercializing novel oncology therapies. Their business model involves leveraging their proprietary enzyme technology to improve the delivery and effectiveness of therapeutic drugs. By partnering with pharmaceutical companies, Halozyme aims to license their technology and collaborate on the development and commercialization of innovative therapies for various diseases.
Sources:
Neumora Therapeutics Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Neumora Therapeutics Inc versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
